PE20010580A1 - PHARMACEUTICAL COMPOSITION TO TREAT DIABETES - Google Patents
PHARMACEUTICAL COMPOSITION TO TREAT DIABETESInfo
- Publication number
- PE20010580A1 PE20010580A1 PE2000000887A PE0008872000A PE20010580A1 PE 20010580 A1 PE20010580 A1 PE 20010580A1 PE 2000000887 A PE2000000887 A PE 2000000887A PE 0008872000 A PE0008872000 A PE 0008872000A PE 20010580 A1 PE20010580 A1 PE 20010580A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alcoxycarbonyl
- carboxyl
- pharmaceutical composition
- ora
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 METHYLENDIOXYL FORM Chemical group 0.000 abstract 7
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 150000002430 hydrocarbons Chemical group 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229940122355 Insulin sensitizer Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 229960004586 rosiglitazone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN SENSIBILIZADOR DE INSULINA EN COMBINACION CON a)UN COMPUESTO I, R1 ES ALQUILO SUSTITUIDO POR OH, FENILSULFONILAMINO, ALQUILSULFONILAMINO, MONOALQUILAMINOSULFONILO, XaRa, -[O(CH2)p-CH(Rb)]qRbb, -O(CH2)r-Rc, Ya-(CH2)s-Rd O JUNTO CON R2 FORMA METILENDIOXILO OPCIONALMENTE SUSTITUIDO POR CARBOXILO, ALCOXICARBONILO, Ra ES H, ALQUILO, Ra ES ALQUILO CUANDO Xa ES S, Rb ES H, ALQUILO, ALCOXICARBONILO, CARBOXILO, Rbb ES ALCOXICARBONILO, CARBOXILO, p ES 0-3; q ES 0-1; Rc ES ALCANOILO, HIDROXILO, CIANO, FENILO, ALQUILAMINOCARBONILO, P(=O)(ORA)(ORA), RA ES H, ALQUILO; r ES 1-4; Ya ES HN, S, Rd ES CARBOXILO, ALCOXICARBONILO; s ES 1-4; R2 ES H, HALOGENO, ALQUILO, OH, ALCOXILO; R3 ES H, ALQUILO; W ES 2-, 3-INDOL; b)UN COMPUESTO IV, R ES UN HIDROCARBURO, HETEROCICLO; Y ES CO, CHOH, NR3; R3 ES ALQUILO; m ES 0-1; n ES 0-2; X ES CH, N; A ES UN ENLACE, HIDROCARBURO; Q ES O, S; R1 ES H, ALQUILO; L Y M SON H DE PREFERENCIA ES PIOGLITAZONA, ROSIGLITAZONA, EN COMBINACION CON 2-[3-(7-CARBOXIMETOXIINDOL-3-IL)-(2R)-2-PROPILAMINO]-(1R)-1-(3-CLOROFENIL)ETANOL. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES, TOLERANCIA A GLUCOSA DISMINUIDA, HIPERLIPIDEMIA, HIPERINSULINEMIA, OBESIDAD, HIPERFAGIA, HIPERTENSION, RETINOPATIA, NEFROPATIA, PARA INHIBIR EL AUMENTO DE PESOREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING AN INSULIN SENSITIZER IN COMBINATION WITH a) A COMPOUND I, R1 IS ALKYL SUBSTITUTED BY OH, PHENYLSULFONYLAMINE, ALKYLSULFONYLAMINE, MONOALKYLAMINES, OR (qRB2) -PUBLPHONYL, Xab) (q) CHULFONYL. , -O (CH2) r-Rc, Ya- (CH2) s-Rd OR TOGETHER WITH R2 METHYLENDIOXYL FORM OPTIONALLY REPLACED BY CARBOXYL, ALCOXYCARBONYL, Ra IS H, ALKYL, Ra IS RENT WHEN Xa IS S, Rb IS H, ALKYL , ALCOXYCARBONYL, CARBOXYL, Rbb IS ALCOXYCARBONYL, CARBOXYL, p IS 0-3; q IS 0-1; Rc IS ALKANOYL, HYDROXYL, CYANE, PHENYL, ALKYLAMINE CARBONYL, P (= O) (ORA) (ORA), RA IS H, ALKYL; r IS 1-4; Ya IS HN, S, Rd IS CARBOXYL, ALCOXYCARBONYL; s IS 1-4; R2 IS H, HALOGEN, ALKYL, OH, ALCOXYL; R3 IS H, ALKYL; W ES 2-, 3-INDOL; b) A COMPOUND IV, R IS A HYDROCARBON, HETEROCICLO; Y IS CO, CHOH, NR3; R3 IS RENT; m IS 0-1; n IS 0-2; X IS CH, N; A IS A LINK, HYDROCARBON; Q IS O, S; R1 IS H, ALKYL; L AND M ARE H OF PREFERENCE IS PIOGLITAZONE, ROSIGLITAZONE, IN COMBINATION WITH 2- [3- (7-CARBOXIMETOXIINDOL-3-IL) - (2R) -2-PROPYLAMINO] - (1R) -1- (3-CHLOROPHENYL) ETHANOL. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF DIABETES, DECREASED GLUCOSE TOLERANCE, HYPERLIPIDEMIA, HYPERINSULINEMIA, OBESITY, HYPERPHAGIA, HYPERTENSION, RETINOPATHY, NEPHROPATIA, TO INHIBIT PYRONIC INCREASE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25044399 | 1999-09-03 | ||
| JP2000056021 | 2000-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010580A1 true PE20010580A1 (en) | 2001-05-25 |
Family
ID=26539777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000887A PE20010580A1 (en) | 1999-09-03 | 2000-08-29 | PHARMACEUTICAL COMPOSITION TO TREAT DIABETES |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1212090A2 (en) |
| KR (1) | KR20020063555A (en) |
| CN (1) | CN1372476A (en) |
| AR (1) | AR031674A1 (en) |
| AU (1) | AU6868000A (en) |
| CA (1) | CA2383946A1 (en) |
| CO (1) | CO5180632A1 (en) |
| HK (1) | HK1044711A1 (en) |
| HU (1) | HUP0203285A3 (en) |
| NO (1) | NO20021036L (en) |
| PE (1) | PE20010580A1 (en) |
| PL (1) | PL354295A1 (en) |
| RU (1) | RU2002108346A (en) |
| WO (1) | WO2001017513A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1354602B1 (en) | 2000-12-26 | 2006-10-04 | Sankyo Company, Limited | Medicinal compositions containing diuretic and insulin resistance-improving agent |
| ATE423559T1 (en) | 2001-04-04 | 2009-03-15 | Ortho Mcneil Janssen Pharm | COMBINATION THERAPY USING GLUCOSE ABSORPTION INHIBITORS AND PPAR MODULATORS |
| DE60233655D1 (en) | 2001-04-04 | 2009-10-22 | Ortho Mcneil Janssen Pharm | R AND RETINOID X RECEPTOR MODULATORS |
| FR2838968A1 (en) * | 2002-04-30 | 2003-10-31 | Lipha | ASSOCIATION OF INSULIN AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR TREATING DIABETES |
| KR20050010512A (en) | 2002-06-12 | 2005-01-27 | 스미또모 세이야꾸 가부시키가이샤 | Indole, indazole and benzazole derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4649189A (en) * | 1988-11-14 | 1990-06-12 | Upjohn Company, The | Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
| AU651571B2 (en) * | 1990-02-09 | 1994-07-28 | Pharmacia & Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
| AU688165B2 (en) * | 1994-11-29 | 1998-03-05 | Dainippon Pharmaceutical Co. Ltd. | Indole derivative |
-
2000
- 2000-08-29 PE PE2000000887A patent/PE20010580A1/en not_active Application Discontinuation
- 2000-08-30 AR ARP000104514A patent/AR031674A1/en not_active Application Discontinuation
- 2000-09-01 AU AU68680/00A patent/AU6868000A/en not_active Abandoned
- 2000-09-01 HU HU0203285A patent/HUP0203285A3/en unknown
- 2000-09-01 KR KR1020027002851A patent/KR20020063555A/en not_active Application Discontinuation
- 2000-09-01 CO CO00065981A patent/CO5180632A1/en not_active Application Discontinuation
- 2000-09-01 EP EP00956872A patent/EP1212090A2/en not_active Withdrawn
- 2000-09-01 CN CN00812420A patent/CN1372476A/en active Pending
- 2000-09-01 CA CA002383946A patent/CA2383946A1/en not_active Abandoned
- 2000-09-01 RU RU2002108346/14A patent/RU2002108346A/en not_active Application Discontinuation
- 2000-09-01 PL PL00354295A patent/PL354295A1/en not_active Application Discontinuation
- 2000-09-01 WO PCT/JP2000/005951 patent/WO2001017513A2/en not_active Application Discontinuation
-
2002
- 2002-03-01 NO NO20021036A patent/NO20021036L/en not_active Application Discontinuation
- 2002-08-15 HK HK02105969.4A patent/HK1044711A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001017513A3 (en) | 2001-09-20 |
| CA2383946A1 (en) | 2001-03-15 |
| HUP0203285A3 (en) | 2003-02-28 |
| RU2002108346A (en) | 2003-11-20 |
| PL354295A1 (en) | 2004-01-12 |
| HUP0203285A2 (en) | 2003-01-28 |
| CN1372476A (en) | 2002-10-02 |
| AU6868000A (en) | 2001-04-10 |
| HK1044711A1 (en) | 2002-11-01 |
| WO2001017513A2 (en) | 2001-03-15 |
| NO20021036D0 (en) | 2002-03-01 |
| KR20020063555A (en) | 2002-08-03 |
| AR031674A1 (en) | 2003-10-01 |
| EP1212090A2 (en) | 2002-06-12 |
| NO20021036L (en) | 2002-04-26 |
| CO5180632A1 (en) | 2002-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2312106C2 (en) | Substituted 4-alkoxyoxazol derivatives as ppar agonists | |
| KR950702982A (en) | Substituted Thiazolidinedione Derivatives | |
| CO5440230A1 (en) | NEW HETEROCICLIC COMPOUND INCLUDING TETRAHYDROISOQUINOLINE AND A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME | |
| KR970706812A (en) | METHOD AND COMPOSITIONS FOR INHIBITING PROTEIN KINASES | |
| KR880002834A (en) | α-alkyl-4-amino-3-quinolinmethanol and 1- (4-aralkylamino-3-quinolinyl) alkanones, methods for their preparation and use as medicaments | |
| LU91926I2 (en) | Belimumab and its pharmaceutically acceptable derivatives (Benlysta®) | |
| KR960014121A (en) | Aroyl-piperidine derivatives | |
| EA200300323A1 (en) | DERIVATIVES OF GUANIDININOBENZAMIDE (OPTIONS), COMPOSITION (OPTIONS), METHOD OF TREATMENT OF MEDIATED DISTRIBUTIONS mc4-r | |
| BRPI0108977B8 (en) | azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof | |
| ATE235476T1 (en) | THIAZOLIDINDIONE DERIVATIVES, THEIR PREPARATION AND USE | |
| ATE420090T1 (en) | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | |
| CY1107500T1 (en) | USE OF FLUMAZENIL IN THE DEVELOPMENT OF A DRUG FOR THE ALTERNATIVE TREATMENT OF ALCOHOL ADDICTION | |
| KR920000749A (en) | 1-indolylalkyl-4- (alkoxypyrimidinyl) piperazine | |
| PE20010580A1 (en) | PHARMACEUTICAL COMPOSITION TO TREAT DIABETES | |
| AR043259A1 (en) | METHOD FOR THE TREATMENT OF SEVERE CARDIAC INSUFFICIENCY AND MEDICATION FOR IT | |
| RU2008126389A (en) | DERIVATIVES OF 1,1-DIOXOTHIOMORPHOLINYLINDOLYLMYL METHANONE FOR USE AS HISTAMINASE (H3) MODULATORS | |
| KR960700696A (en) | 5-HT2RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS | |
| EA200601144A1 (en) | TABLET OF SLOW-DOWN PREVENTION OF INSULIN SENSITIZER TO INSULIN | |
| AR012997A1 (en) | USE OF 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIDIN-2,4- DIONA AND INSULIN FOR THE PREPARATION OF MEDICINES, AND CONTAINING PHARMACEUTICAL COMPOSITION. | |
| ATE254122T1 (en) | INDOLE DERIVATIVES AS 5-HT1B AND 5-HT1D AGONISTS | |
| KR900700098A (en) | Plaboxate and its derivatives for the treatment and diagnosis of erectile dysfunction | |
| DE50312523D1 (en) | Pharmaceutical Composition and its use | |
| KR880007462A (en) | Propiophenone Derivatives for the Treatment of Frequency | |
| RU2005141559A (en) | METHOD FOR TREATING AND PREVENTING SYMPTOMS OF THE LOWER DEPARTMENT OF THE URINE | |
| PE108199A1 (en) | PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND SULFONILUREA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |